fig3

Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance

Figure 3. Overcoming breast cancer therapeutic resistance by MED1 targeting multifunctional RNA nanoparticles. The figure shows the atomic force microscopy (A) and schematic (B) of the pRNA-HER2apt-MED1siRNA nanoparticle, its tumor-specific uptake in vitro and in vivo (C), and therapeutic effect to inhibit endocrine-resistant tumor growth (D), cancer stem cell formation (E), and lung metastasis (F) in vivo in an orthotopic xenograft mouse model. **P < 0.01, ***P < 0.001. Adapted from Zhang et al.[88], ACS Nano.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/